31 research outputs found
The changing role of beta-blocker therapy in patients with cirrhosis
Get PDFSummaryCirrhosis is a leading cause of death in the United States and worldwide. Beta-blockers have been established in numerous studies as part of the cornerstone of the medical management of cirrhosis, particularly in the primary and secondary prevention of variceal hemorrhage. However, new evidence has cautioned the use of beta-blockers in patients with end-stage cirrhosis and refractory ascites. In this article, we review the beneficial effects of beta-blocker therapy, the potential harms of aggressive beta-blocker therapy, and provide suggestions regarding the appropriate use of this class of medications in patients with cirrhosis
Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome
Full text linkLower than expected hepatitis B virus infection prevalence among first generation Koreans in the U.S.: results of HBV screening in the Southern California Inland Empire
Full text linkAscitic Fluid and Serum C-Reactive Protein Concentrations in Patients with and without Peritonitis
No full text
The Opacity of Portal Hypertension-Related Ascites Correlates with the Fluid's Triglyceride Concentration
No full textSa1036 Early Diagnostic Paracentesis in Spontaneous Bacterial Peritonitis is Associated With Low in-Hospital Mortality
No full textRapid Resolution of Hepatitis C Virus–Associated Cryoglobulin Rash With Use of Direct-Acting Antivirals
No full text
